Evidence map›Paper›PMID 42526441›Full record

ArticleCell reports. Medicine2026

Persistent cytolytic CD8

Tongcui Ma, Heeju Ryu, Kailin Yin, Thomas Dalhuisen, Douglas Robbins, Tyrine T Bailey, Sean A Thomas, Emily A Fehrman, J Daniel Kelly, Jeffrey N Martin and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tongcui MaGladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
Heeju RyuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Kailin YinGladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
Thomas DalhuisenDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Douglas RobbinsDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Tyrine T BaileyDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sean A ThomasDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Emily A FehrmanDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
J Daniel KellyDepartment of Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, USA.
Jeffrey N MartinDepartment of Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, USA.
Kara L LynchDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sulggi A LeeZuckerberg San Francisco General Hospital and the University of California, San Francisco, San Francisco, CA, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Evan W NewellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: enewell@fredhutch.org.
Nadia R RoanGladstone Institutes, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: nadia.roan@gladstone.ucsf.edu.

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Systems Biology CoreU19AI128914 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Margaret Juliana McElrath, KENNETH D STUART · 2017 to 2026
$29.5M
Evaluating SARS-CoV-2 spike antigen-induced coagulopathy and neuroinflammation as mechanistic drivers of neurologic PASCR01NS136197 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Michael Joseph Peluso · 2024 to 2026
$2.0M
Assessing the mechanisms underlying female sex-predominance in Long COVIDR01AI193318 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Michael Joseph Peluso, Nadia R Roan · 2025 to 2026
$1.8M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
NIAID NIH HHS K23 AI157875NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI193318NIAID NIH HHS U19 AI128914NIAID NIH HHS UM1 AI068618NINDS NIH HHS R01 NS136197
6 · The paper itself

Abstract

Viral-specific CD8

Indexed as

CD8-Positive T-LymphocytesCOVID-19Epitopes, T-LymphocyteSARS-CoV-2T-Lymphocytes, CytotoxicCytomegalovirusFemaleGranzymesHerpesvirus 4, HumanHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeEpitopes, T-LymphocyteGranzymesCD8+ T cellsCMVcytolyticEBVgranzymelong COVIDSARS-CoV-2

Identifiers

PMID42526441
PMCPMC13522799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.